Desentum is a clinical-stage, research-oriented biopharmaceutical company specialized in developing novel types of allergy immunotherapy products (aka allergy vaccines) that are based on switching the immune system's response to allergens from hypersensitivity to tolerance. We have a unique approach for designing allergy vaccines. By studying the molecular mechanism of the hypersensitivity reaction, we have made discoveries that allow for improved design of vaccines against common types of allergies. Our goal is to provide long-term relief from allergic symptoms with only a few months of treatment, as well as reduce the social and economic burden allergies cause to both individuals and society.
View Top Employees from Desentum OyWebsite | http://www.desentum.com |
Revenue | $5.3 million |
Funding | $15.5 million |
Employees | 7 (7 on RocketReach) |
Founded | 2011 |
Address | 13 Perustie A 7, Helsinki, Uusimaa 00330, FI |
Phone | +358 50 0512934 |
Industry | Biotechnology, Pharmaceutical Manufacturing, Business Services General, Immunotherapy, Business Services, Science and Engineering, Pharmaceuticals, Allergy Vaccines, Pharmaceutical, Health Care |
Web Rank | 4 Million |
Keywords | Pre Sensitized Mast Cells, Sensitised Pollen, Sensitization In Immunology |
SIC | SIC Code 283 Companies, SIC Code 28 Companies, SIC Code 873 Companies, SIC Code 87 Companies |
NAICS | NAICS Code 3254 Companies, NAICS Code 32541 Companies, NAICS Code 325 Companies, NAICS Code 32 Companies, NAICS Code 54 Companies, NAICS Code 541 Companies |
Looking for a particular Desentum Oy employee's phone or email?
The Desentum Oy annual revenue was $5.3 million in 2024.
Dirk-Jan Opstelten is the Board Member of Desentum Oy.
7 people are employed at Desentum Oy.
Desentum Oy is based in Helsinki, Uusimaa.
The NAICS codes for Desentum Oy are [3254, 32541, 325, 32, 54, 541].
The SIC codes for Desentum Oy are [283, 28, 873, 87].